Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Helix Nanotechnologies
AddedFeb 15, 2024
UpdatedJul 3, 2026
Helix Nanotechnologies

Helix Nanotechnologies

Series A

HelixNano: Pioneering mRNA tech for cancer, COVID, and eco solutions.

HQ
Cambridge, MA, US
Founded
2013
Accelerator
Y Combinator logoY CombinatorW17
Overview
Compare
Fundraising
Employees
Website

Helix Nanotechnologies, founded with a mission to revolutionize healthcare and environmental solutions through advanced mRNA technology, aims to make treatments more affordable and accessible. The company focuses on developing next-generation mRNA platforms to combat cancer, COVID-19, and climate-related challenges. By leveraging first-principles improvements in mRNA, HelixNano accelerates experimental timelines and reduces costs significantly, enabling rapid biological modifications.

Notable figures affiliated with Helix Nanotechnologies include Justin Huang, a Bioinformatics Pathfinder, and Julia Carvalho, the COO. The company has made significant strides in mRNA technology, achieving faster and more cost-effective experimental processes. HelixNano's impact is evident in its innovative approach to enhancing the immune system's ability to fight diseases, positioning it as a leader in the biotech space.

Helix Nanotechnologies - Similar Companies

Helixomer logo

Helixomer

helixomer.com

Nano Cures logo

Nano Cures

nanocures.com

Rnaimmune logo

Rnaimmune

rnaimmune.com

Sensible Biotechnologies logo

Sensible Biotechnologies

sensible.bio

Helix logo

Helix

Helixbind logo

Helixbind

helixbind.com

Nano RED logo

Nano RED

Moderna logo

Moderna

modernatx.com

Mana.bio logo

Mana.bio

mana.bio

Cisterna Biologics logo

Cisterna Biologics

cisternabx.com

Rejuvenation Technologies Inc. logo

Rejuvenation Technologies Inc.

Nanopath logo

Nanopath

nanopathdx.com

HDT Bio logo

HDT Bio

hdt.bio

Helix BioMedix logo

Helix BioMedix

helixbiomedix.com

Nanite logo

Nanite

nanitebio.com

Helix Nanotechnologies - Quick Facts

Who are Helix Nanotechnologies' competitors?

Companies similar to Helix Nanotechnologies include Helixomer, Nano Cures, Rnaimmune and Sensible Biotechnologies.

When was Helix Nanotechnologies founded?

Helix Nanotechnologies was founded in 2013.

Where is Helix Nanotechnologies' headquarters located?

Helix Nanotechnologies' headquarters is located in Cambridge, MA, US.

How much has Helix Nanotechnologies raised to-date?

As of Sep 5, 2022, Helix Nanotechnologies has raised a total of $58.6M (USD).

How many employees does Helix Nanotechnologies have?

Helix Nanotechnologies has 16 employees as of Mar 22, 2024.

Helix Nanotechnologies - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Mrna Therapies
  • Vaccines
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software